Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system intellectual property within the biodefense and Alzheimer’s disease fields. In exchange, Oncotelic received $12.5 million in Series B convertible preferred stock. The agreement establishes an initiative focused on central nervous system (CNS)-targeted therapeutics while supporting the company’s strategy to monetize its portfolio and retain control of core assets.
The N2B platform enables intranasal delivery directly to the central nervous system, bypassing the blood-brain barrier to support rapid therapeutic action and targeted neurological engagement. This technology has applications in biodefense medical countermeasures and neurodegenerative conditions. Under the agreement, Lunai Bioworks will develop the platform within the specified fields, while Oncotelic retains rights for other indications, including Parkinson’s disease and sexual dysfunction, leveraging internal expertise in CNS therapeutics and biodefense.
This transaction is significant for the industry as it highlights a novel approach to delivering therapeutics to the brain, a longstanding challenge in drug development. The blood-brain barrier often limits the effectiveness of systemic treatments for neurological disorders. By enabling direct nose-to-brain delivery, the N2B platform could accelerate the development of countermeasures for biological threats and treatments for Alzheimer’s disease, which affects millions worldwide. For Oncotelic, the deal provides non-dilutive capital through preferred stock, strengthening its financial position while allowing the company to focus on other pipeline assets.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company also benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.
For investors, the move demonstrates Oncotelic’s ability to monetize its intellectual property while retaining strategic control. The company’s focus on CNS-targeted therapeutics and biodefense aligns with growing government and commercial interest in pandemic preparedness and neurological disease treatments. The full press release is available at https://ibn.fm/IWUpe. For the latest news and updates on OTLC, visit the company’s newsroom at https://ibn.fm/OTLC.
